Mucormycosis in COVID-19 Pandemic
DOI:
https://doi.org/10.17140/OTLOJ-8-167Keywords:
Coronavirus, Mucormycosis, Fungal infectionAbstract
Background
Coronavirus disease-2019 (COVID-19) has been associated with a wide range of opportunistic fungal infections. Many coun-tries have seen an unprecedented rise in cases of COVID-19-associated mucormycosis (CAM). The purpose of this study is to identify the correlation between the COVID-19 epidemic and mucormycosis. Our study also provides details on factors causing CAM.
Methods
A retrospective study from November 2020 to February 2022 includes four cases of COVID-19-associated rhino-orbital mucormycosis treated at Habib Thameur Hospital’s ENT Department.
Results
The mean age of patients was 67.5-years, 75% were males, and the most frequent underlying conditions were diabetes mellitus (100%). The median time interval between the diagnosis of COVID-19 and the first evidence of mucormycosis infection was 15-days; two patients required hospitalization in a COVID unit, and two patients received oxygen therapy at home. All patients received corticosteroid therapy at a dose of 1 mg/kg/d for an average of 10-days. Treatment using antifungals and surgery was described in all the patients. Amphotericin B deoxycholate was used in 75% and lipid formulation in 25%. Two patients pre-sented renal insufficiency due to amphotericin B; the doses were adapted with good evolution. In that report, the case fatality rate was 75%.
Conclusion
Mucormycosis is a fatal fungal infection that usually affects patients with altered immunity. Several cases of mucormycosis in people with COVID-19 have been increasingly reported worldwide. Diabetes mellitus (DM), steroid overdose, immunosuppres-sion, and high iron levels, combined with other factors such as prolonged hospitalization, unhygienic conditions, and the use of ventilators, combine to create an ideal environment for contracting mucormycosis. Lastly, there is a need to create awareness about fungal diseases among clinicians in order to help identify early symptoms and restrict the spread of lethal fungal diseases. A collaborative team of otolaryngologists, ophthalmologists, anesthesiologists, and resuscitators will be required in hospitals to accelerate optimal management.
References
Ravindra K, Ahlawat A. Five probable factors responsible for the COVID-associated mucormycosis outbreak in India. Int J Infect Dis. 2021; 112: 278-280. doi: 10.1016/j.ijid.2021.09.057
Bhanuprasad K, Manesh A, Devasagayam E, et al. Risk factors associated with the mucormycosis epidemic during the COV-ID-19 pandemic. Int J Infect Dis. 2021; 111: 267-270. doi: 10.1016/j. ijid.2021.08.037
Chao CM, Lai CC, Yu WL. COVID-19 associated mucormy-cosis – An emerging threat. J Microbiol Immunol Infect. 2022; 55(2): 183-190. doi: 10.1016/j.jmii.2021.12.007
Balushi AA, Ajmi AA, Sinani QA, et al. COVID-19-associat-ed mucormycosis: An opportunistic fungal infection. A case se-ries and review. Int J Infect Dis. 2022; 121: 203-210. doi: 10.1016/j. ijid.2022.05.005
Bhanuprasad K, Varghese GM, S AM. Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic. Int J Infect Dis. 2022; 116: S55-S56. doi: 10.1016/j.ijid.2021.12.132
John TM, Jacob CN, Kontoyiannis DP. When uncontrolled dia-betes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis. J Fungi (Basel). 2021; 7(4): 298. doi: 10.3390/ jof7040298
Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter epi-demiologic study of coronavirus disease-associated mucormyco-sis, India. Emerg Infect Dis. 2021; 27(9): 2349-2359. doi: 10.3201/ eid2709.210934
Buil JB, van Zanten ARH, Bentvelsen RG, et al. Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. Euro Surveill. 2021;26:2100510. doi: 10.2807/1560-7917.ES.2021.26.23.2100510
Pakdel F, Ahmadikia K, Salehi M, et al. Mucormycosis in pa-tients with COVID-19: Across-sectional descriptive multicenter study from Iran. Mycoses. 2021; 64(10): 1238-1252. doi: 10.1111/ myc.13334
Selarka L, Sharma AK, Rathod G, Saini D, Patel S, Sharma VK. Mucormycosis: A dreaded complication of COVID-19. QJM. 2021; 114(9): 670-671. doi: 10.1093/qjmed/hcab166
Karimi-Galougahi M, Arastou S, Haseli S. Fulminant mucor-mycosis complicating coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol. 2021; 11(6): 1029-1030. doi: 10.1002/alr.22785
Mekonnen ZK, Ashraf DC, Jankowski T, et al. Acute invasive rhino-orbital mucormycosisina patient with COVID-19-associated acute respiratory distresssyndrome. Ophthalmic Plast Reconstr Surg. 2021; 37: e40-e80. doi: 10.1097/IOP.0000000000001889
Fouad YA, Abdelaziz TT, Askoura A, et al. Spike in rhino-orbit-Retrospective Study | Volume 8 | Number 1 | al-cerebral mucormycosiscases presenting to a tertiary care center during the COVID-19 pandemic. Front Med (Lausanne). 2021; 8: 645270. doi: 10.3389/fmed.2021.645270
Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosisduringsteroidtherapy in COVID-19 patients: A case report. Eur J Ophthalmol. 2022; 32(4): NP11-NP16. doi: 10.1177/11206721211009450
Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calle-jaAlarcon S, Romero-Gutierrez L. A case of fatal rhino-orbital-mucormycosis associated with new onset diabetic ketoacidosis and Submit your article to this journal | https://openventio.org/submit-manuscript/ Retrospective Study | Volume 8 | Number 1 | Farjallah H, et al COVID 19. Cureus. 2021; 13: e13163. doi: 10.7759/cureus.13163
Garg D, Muthu V, Sehgal IS, et al. Coronavirus disease (COV-ID-19) associated mucormycosis (CAM): Case report and system-atic review of literature. Mycopathologia. 2021; 186: 289-298. doi: 10.1007/s11046-021-00528-2
Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyas-reeV.Sino-orbital mucormycosis in a COVID-19 patient: A case report. Int J Surg Case Rep. 2021; 82: 105957. doi: 10.1016/j. ijscr.2021.105957
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Otolaryngology (OOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
